Growth factor therapy and lymph node graft for lymphedema

Area of Science:

• Biomedical research
• Regenerative medicine
• Lymphatic system biology

Background:

• Secondary lymphedema is a significant complication following cancer treatment, particularly in breast cancer patients.
• Current treatments for lymphedema remain limited, highlighting the need for novel therapeutic strategies.
• The lymphatic network's regeneration is a key target for lymphedema treatment.

Purpose of the Study:

• To evaluate the efficacy of lymphatic vascular growth factor therapy combined with lymph node transfer for lymphedema regeneration.
• To compare the lymphangiogenic effects of different vascular endothelial growth factors (VEGF-C, VEGF-D, VEGF-C156S, VEGF-A).

Main Methods:

• A mouse model of lymphedema was utilized to assess therapeutic interventions.
• Different vascular endothelial growth factors (VEGF-C, VEGF-D, VEGF-C156S, VEGF-A) were administered in combination with lymph node transfer.
• Lymphangiogenic effects and lymphatic vessel function were evaluated three months post-surgery.

Main Results:

• Vascular endothelial growth factor-C (VEGF-C) and VEGF-D significantly induced new lymphatic vessel growth and improved lymphatic function.
• VEGF-C demonstrated the most robust lymphangiogenic response and superior therapeutic effect.
• Prolymphangiogenic growth factors enhanced lymph node survival compared to VEGF-A and control groups.

Conclusions:

• Combining lymph node transfer with vascular endothelial growth factor therapy offers a viable strategy for treating secondary lymphedema.
• VEGF-C is identified as the preferred growth factor for lymphedema therapy due to its potent lymphangiogenic properties and minimal impact on blood vessels.